Leveraging the Power of ASOs to Target the Expression of NLRP3 for Enhanced Specificity of Inflammasome Inhibition

Time: 12:00 pm
day: Day 1


  • Utilizing ASOs to specifically target NLRP3 expression for comprehensive inflammasome inhibition
  • Demonstrating potent reduction in Caspase-1 activity and complete blockade of mature IL-1β release with NLRP3-specific ASOs
  • Systemic administration of NLRP3-specific ASOs in a mouse model of CAPS shows prolonged survival and significant reduction in systemic inflammation, paving the way for potential ASO therapy in NLRP3-mediated diseases